These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28100629)

  • 1. Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia.
    Karunasena N; Margetson DN; Neal G; Whitaker MJ; Ross RJ
    Eur J Endocrinol; 2017 Apr; 176(4):405-411. PubMed ID: 28100629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia.
    Mallappa A; Sinaii N; Kumar P; Whitaker MJ; Daley LA; Digweed D; Eckland DJ; Van Ryzin C; Nieman LK; Arlt W; Ross RJ; Merke DP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):1137-45. PubMed ID: 25494662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia.
    Verma S; Vanryzin C; Sinaii N; Kim MS; Nieman LK; Ravindran S; Calis KA; Arlt W; Ross RJ; Merke DP
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):441-7. PubMed ID: 19486026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion.
    Charmandari E; Pincus SM; Matthews DR; Johnston A; Brook CG; Hindmarsh PC
    J Clin Endocrinol Metab; 2002 May; 87(5):2238-44. PubMed ID: 11994370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations.
    Hindmarsh PC; Charmandari E
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):557-61. PubMed ID: 25369980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Charmandari E; Johnston A; Brook CG; Hindmarsh PC
    J Endocrinol; 2001 Apr; 169(1):65-70. PubMed ID: 11250647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.
    Melin J; Parra-Guillen ZP; Michelet R; Truong T; Huisinga W; Hartung N; Hindmarsh P; Kloft C
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32052005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.
    Whitaker M; Debono M; Huatan H; Merke D; Arlt W; Ross RJ
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):554-561. PubMed ID: 23980724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing oral chronotherapy for cortisol replacement in congenital adrenal hyperplasia.
    Whitaker MJ; Debono M; Ross RJ
    Clin Endocrinol (Oxf); 2024 Oct; 101(4):311-317. PubMed ID: 37767979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia.
    Charmandari E; Calis KA; Keil MF; Mohassel MR; Remaley A; Merke DP
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3197-200. PubMed ID: 12107224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.
    Johannsson G; Bergthorsdottir R; Nilsson AG; Lennernas H; Hedner T; Skrtic S
    Eur J Endocrinol; 2009 Jul; 161(1):119-30. PubMed ID: 19383806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia.
    Prete A; Auchus RJ; Ross RJ
    Eur J Endocrinol; 2021 Nov; 186(1):R1-R14. PubMed ID: 34735372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is physiological glucocorticoid replacement important in children?
    Porter J; Blair J; Ross RJ
    Arch Dis Child; 2017 Feb; 102(2):199-205. PubMed ID: 27582458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal glucocorticoid therapy.
    Debono M; Ross RJ
    Endocr Dev; 2011; 20():173-180. PubMed ID: 21164270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The child with difficult to control Congenital Adrenal Hyperplasia: is there a place for continuous subcutaneous hydrocortisone therapy.
    Hindmarsh PC
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):15-8. PubMed ID: 24655023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congenital adrenal hyperplasia: management during critical illness.
    Charmandari E; Lichtarowicz-Krynska EJ; Hindmarsh PC; Johnston A; Aynsley-Green A; Brook CG
    Arch Dis Child; 2001 Jul; 85(1):26-8. PubMed ID: 11420193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise.
    Weise M; Drinkard B; Mehlinger SL; Holzer SM; Eisenhofer G; Charmandari E; Chrousos GP; Merke DP
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3679-84. PubMed ID: 15292287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia.
    Charmandari E; Johnston A; Honour JW; Brook CG; Hindmarsh PC
    J Pediatr Endocrinol Metab; 2002 Apr; 15(4):435-9. PubMed ID: 12008691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.